Sign Up to like & get
recommendations!
0
Published in 2020 at "Expert Opinion on Biological Therapy"
DOI: 10.1080/14712598.2020.1717464
Abstract: ABSTRACT Introduction: Multiple myeloma (MM) is characterized by the uncontrollable proliferation of plasma cells and the excessive production of a specific type of immunoglobulin. Immune system is deregulated in MM and, thus, immunotherapy is a…
read more here.
Keywords:
myeloma;
antibody therapies;
multiple myeloma;
therapies multiple ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2019 at "Cold Spring Harbor perspectives in medicine"
DOI: 10.1101/cshperspect.a032037
Abstract: B cells play a vital function in multiple sclerosis (MS) pathogenesis through an array of effector functions. All currently approved MS disease-modifying therapies alter the frequency, phenotype, or homing of B cells in one way…
read more here.
Keywords:
multiple sclerosis;
cell therapies;
cell;
therapies multiple ... See more keywords
Sign Up to like & get
recommendations!
2
Published in 2023 at "British Journal of Haematology"
DOI: 10.1111/bjh.18711
Abstract: The CD38‐targeting monoclonal antibodies (CD38 mAbs) are well‐established therapies in multiple myeloma (MM), but responses to treatment are not always deep or durable. Natural killer (NK) cells deficient in Fc epsilon receptor gamma subunits, known…
read more here.
Keywords:
centre retrospective;
seropositivity;
therapies multiple;
single centre ... See more keywords
Sign Up to like & get
recommendations!
2
Published in 2019 at "Croatian Medical Journal"
DOI: 10.3325/cmj.2019.60.87
Abstract: Increasing evidence suggests that B cells contribute both to the regulation of normal autoimmunity and to the pathogenesis of immune mediated diseases, including multiple sclerosis (MS). B cells in MS are skewed toward a pro-inflammatory…
read more here.
Keywords:
sclerosis;
sclerosis targeting;
pathology;
multiple sclerosis ... See more keywords